Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00513071 · ClinicalTrials.gov registry record · Phase 2
AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00513071: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00513071 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00513071, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This phase II trial is studying how well AZD0530 works in treating patients with prostate cancer that did not respond to hormone therapy. AZD0530 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Interventions
- OTHER laboratory biomarker analysis
- DRUG saracatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00513071
The ClinicalTrials.gov registry entry for NCT00513071 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00513071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00513071 about?
NCT00513071 is a clinical study titled "AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy". This phase II trial is studying how well AZD0530 works in treating patients with prostate cancer that did not respond to hormone therapy. AZD0530 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
What is the current status of trial NCT00513071?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2007-08. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00513071?
The interventions under investigation include: laboratory biomarker analysis (OTHER), saracatinib (DRUG).
Who is sponsoring clinical trial NCT00513071?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.